|Articles|July 1, 2020
67.3% of Trials Disrupted by COVID-19 are Due to Enrollment Suspension
Advertisement
GlobalData has found that the majority of disrupted clinical trials 67.3%, were due to the suspension of enrollment. The delayed initiation of planned trials follows at 18.4%, then, 14.4% of trials are currently being impacted due to slow enrollment.
For more information and findings, click
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck
2
SCOPE X: The COPD Case Study That Shows What AI Can Do for Enrollment
3
A Shot in the Arm to Traditional Vaccine Trial Strategy
4
SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years
5